Beactica Therapeutics Chooses BEA-28 for Preclinical Trials as a Novel TEAD Degrader #Sweden #Uppsala #Beactica #BEA-28 #TEAD_degrader
@newsen.bsky.socialExplore
@newsen.bsky.social@newsen.bsky.socialBeactica Therapeutics Selects BEA-28 as a Revolutionary Treatment for Cancer #Sweden #Uppsala #Beactica_Therapeutics #BEA-28 #TEAD_degrader